(NASDAQ: PRTA) Prothena Public Co's forecast annual revenue growth rate of 11.29% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Prothena Public Co's revenue in 2025 is $137,935,000.On average, 6 Wall Street analysts forecast PRTA's revenue for 2025 to be $2,114,377,680, with the lowest PRTA revenue forecast at $150,715,550, and the highest PRTA revenue forecast at $6,207,865,834. On average, 5 Wall Street analysts forecast PRTA's revenue for 2026 to be $4,750,231,162, with the lowest PRTA revenue forecast at $741,197,542, and the highest PRTA revenue forecast at $10,768,087,749.
In 2027, PRTA is forecast to generate $11,215,013,181 in revenue, with the lowest revenue forecast at $5,920,968,020 and the highest revenue forecast at $18,111,702,903.